Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/18/2012CA2716966C Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
12/18/2012CA2702933C Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
12/18/2012CA2683956C Quinolones and azaquinolones that inhibit prolyl hydroxylase
12/18/2012CA2677572C 3-amino-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives as pkc inhibitors
12/18/2012CA2671776C Gal3 receptor antagonists for the treatment of depression
12/18/2012CA2661354C New small molecule inhibitors of mdm2 and the uses thereof
12/18/2012CA2648126C Treatments using citrulline
12/18/2012CA2631732C Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
12/18/2012CA2626627C Androsterone derivatives and method of use thereof
12/18/2012CA2621867C Adhesive pharmaceutical preparation containing bisoprolol
12/18/2012CA2596003C Six-membered heterocyclic compound and use thereof
12/18/2012CA2577758C Gyrase inhibitors and uses thereof
12/18/2012CA2570506C Thienopyridone carboxamides and their medical use
12/18/2012CA2569077C Combinations comprising antimuscarinic agents and corticosteroids
12/18/2012CA2569074C Combinations comprising antimuscarinic agents and pde4 inhibitors
12/18/2012CA2568571C Combinations comprising antimuscarinic agents and corticosteroids
12/18/2012CA2568568C Combinations comprising antimuscarinic agents and beta-adrenergic agonists
12/18/2012CA2568566C Combinations comprising antimuscarinic agents and pde4 inhibitors
12/18/2012CA2565187C Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
12/18/2012CA2563674C .alpha.-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
12/18/2012CA2563575C Enantiomerically pure hexahydropyrrolocyclopentapyridine derivatives
12/18/2012CA2557792C Novel use for pde5 inhibitors
12/18/2012CA2554049C Quinoline derivatives for use as mycobacterial inhibitors
12/18/2012CA2536576C Derivatives of hydroxamic acid as metalloproteinase inhibitors
12/18/2012CA2533812C Substituted cycloalkylidene compounds
12/18/2012CA2525502C Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
12/18/2012CA2519956C Compound
12/18/2012CA2517517C P38 inhibitors and methods of use thereof
12/18/2012CA2511214C Asthma and allergic inflammation modulators
12/18/2012CA2509980C Adenoviral vector vaccine
12/18/2012CA2504665C Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
12/18/2012CA2504385C Thiadiazine compounds and uses thereof
12/18/2012CA2503446C Methods of using substituted tetracycline compounds to modulate rna
12/18/2012CA2491613C An hydroxytyrosol-rich composition from olive vegetation water and method of use thereof
12/18/2012CA2489275C Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests for diagnosis and management of aisnhl
12/18/2012CA2472163C Psoriasin expression by breast epithelial cells
12/18/2012CA2460692C Pesticidal formulations
12/18/2012CA2451173C Vector encoding human globlin gene and use thereof in treatment of hemoglobinopathies
12/18/2012CA2450233C Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
12/18/2012CA2407895C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
12/18/2012CA2402299C Serum free cultivation of primate embryonic stem cells
12/18/2012CA2398064C 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
12/18/2012CA2363486C Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
12/15/2012CA2834497A1 New hexahydropyrroloimidazolone compounds
12/15/2012CA2801835A1 Crystalline forms of thalidomide and processes for their preparation
12/13/2012WO2012171024A2 Enzyme directed assembly of particle theranostics
12/13/2012WO2012171016A1 Organic compounds
12/13/2012WO2012171015A2 Therapeutic combination for cancer treatment
12/13/2012WO2012171008A1 Uses of histone acetyltransferase activators
12/13/2012WO2012171002A1 Synthesis and characterization of second generation benzofuranone ring substituted noscapine analogs
12/13/2012WO2012170979A1 Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
12/13/2012WO2012170976A2 Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
12/13/2012WO2012170952A2 Compounds for targeting drug delivery and enhancing sirna activity
12/13/2012WO2012170931A2 Compounds that modulate intracellular calcium
12/13/2012WO2012170930A1 Lipid nanoparticle compositions and methods for mrna delivery
12/13/2012WO2012170917A2 Reduction of microglia-mediated neurotoxicity by kv1.3 inhibition
12/13/2012WO2012170889A1 Cleavable lipids
12/13/2012WO2012170883A1 Antihistamines combined with dietary supplements for improved health
12/13/2012WO2012170867A1 Novel compounds as modulators of gpr-119
12/13/2012WO2012170839A2 Treatment of neuroinflammatory disease with selective cox1 inhibitors
12/13/2012WO2012170827A2 Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
12/13/2012WO2012170792A1 Atazanavir metabolite derivatives
12/13/2012WO2012170773A1 Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
12/13/2012WO2012170720A2 Methods and compositions for treating brain cancer
12/13/2012WO2012170702A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto
12/13/2012WO2012170664A2 Methods of cancer treatment and prevention through the modulation of sirt4 activity
12/13/2012WO2012170655A1 Silk compositions and methods of using same
12/13/2012WO2012170612A1 Multiparticulate l-carnitine compositions and related methods
12/13/2012WO2012170611A1 Multiparticulate 5-htp compositions and related methods
12/13/2012WO2012170599A1 Neurogenesis by muscarinic receptor modulation
12/13/2012WO2012170573A2 New taccalonolide microtubule stabilizers
12/13/2012WO2012170561A1 N-benzylindole modulators of pparg
12/13/2012WO2012170554A1 N-biphenylmethylindole modulators of pparg
12/13/2012WO2012170546A1 Methods of inhibiting muscle atrophy
12/13/2012WO2012170536A1 [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
12/13/2012WO2012170528A1 5-fluorocytosine as a seed treatment
12/13/2012WO2012170504A2 Treatment of extracellular matrix to reduce inflammation
12/13/2012WO2012170488A1 Multiparticulate s-adenosylmethionine compositions and related methods
12/13/2012WO2012170467A1 Compositions and methods for restoring the stratum corneum and treating dermatological diseases
12/13/2012WO2012170442A1 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
12/13/2012WO2012170439A1 Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
12/13/2012WO2012170384A1 Use of metallocene compounds for cancer treatment
12/13/2012WO2012170378A1 Skin treatments containing pyrroloquinoline quinine (pqq) esters and methods of preparation and use thereof
12/13/2012WO2012170371A1 Compounds as s-nitrosoglutathione reductase inhibitors
12/13/2012WO2012170290A1 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
12/13/2012WO2012170284A1 Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression
12/13/2012WO2012170209A2 Benzofuran-2 carboxamide compounds
12/13/2012WO2012170175A1 Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain
12/13/2012WO2012170098A2 Arbovirus inhibitors and uses thereof
12/13/2012WO2012169973A1 A core-shell nanoparticle
12/13/2012WO2012169934A1 Novel kinase inhibitors
12/13/2012WO2012169863A2 5-carbamoyl-adamantan-2-yl amide derivatives, pharmaceutically acceptable salts thereof and preparation process thereof
12/13/2012WO2012169849A2 Eye-drop composition for preventing or treating ocular diseases
12/13/2012WO2012169827A2 Composition for eyelash growth
12/13/2012WO2012169785A2 Symmetrically structured quinazoline derivatives
12/13/2012WO2012169733A1 Pharmaceutical composition comprising amide derivative inhibiting the growth of cancer cells and non-metallic salt lubricant
12/13/2012WO2012169661A1 Monatin polyvalent metal salt crystal
12/13/2012WO2012169654A1 Carbon-monoxide(co)-assisted inhibition of fatty acid and cholesterol uptake
12/13/2012WO2012169649A1 Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
12/13/2012WO2012169600A1 Amino acid composition
1 ... 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 ... 7860